CASP3 and in situ carcinoma: While control and kinetin groups (0.25 Kn, 0.5 Kn, and 1 Kn) showed nearly comparable caspase-3 expressions, CIS treatment caused a significant increase in the expression of caspase-3 compared to the control group.